At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 366 enrolled
Drug / intervention
Actovegin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, International, Multicenter, Parallel Group, Double-Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of Actovegin 12-Week Treatment Given First Intravenously and Subsequently Orally in Subjects With Peripheral Arterial Occlusive Disease Fontaine Stage IIB
In Brief
A Phase 3 clinical trial evaluating Actovegin and Placebo for Peripheral Arterial Diseases. Completed, enrolled 366 participants across 20 sites in 3 countries.
Detailed Summary
The purpose of the study is to evaluate the efficacy and safety of actovegin in participants with peripheral arterial disease (PAD) Fontaine Stage IIB.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPeripheral Arterial Diseases
CountriesGeorgia, Kazakhstan, Russia
Collaborators--
Timeline
Phase 3CompletedFinished
201820192020202120222023202420252026
First PostedMar 2018
Enrollment StartMay 2018
Primary CompletionMay 2019
Study CompletionAug 2019
TodayJul 2026
First PostedMar 19, 2018
Enrollment StartMay 1, 2018
Primary CompletionMay 28, 2019
Study CompletionAug 28, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.3 years ago
Interventions
Actovegindrug
Actovegin intravenous infusion and tablets.
Placebodrug
Actovegin placebo-matching intravenous infusion and tablets.